Strata Critical Medical (NASDAQ:SRTA) Upgraded at Zacks Research

Zacks Research upgraded shares of Strata Critical Medical (NASDAQ:SRTA) to a hold rating in a research report report published on Thursday,Zacks.com reports.

Several other research firms have also recently weighed in on SRTA. Craig Hallum started coverage on shares of Strata Critical Medical in a research note on Wednesday. They issued a “buy” rating and a $8.00 price objective on the stock. Weiss Ratings assumed coverage on shares of Strata Critical Medical in a research report on Tuesday. They set a “hold (c-)” rating on the stock. Finally, B. Riley Financial began coverage on shares of Strata Critical Medical in a research note on Wednesday. They set a “buy” rating and a $8.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Strata Critical Medical Trading Down 2.6%

Shares of NASDAQ SRTA opened at $4.14 on Thursday. Strata Critical Medical has a 12 month low of $2.35 and a 12 month high of $6.02. The company has a market capitalization of $357.57 million, a price-to-earnings ratio of 8.45 and a beta of 2.05.

Strata Critical Medical Company Profile

Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.